艾滋病,动物实验 z-bo 2020-12-17 330

　　A research team in the United States reported that they have developed a treatment that can protect monkeys from the monkey version of HIV (SHIV) for nearly 6 months with just one injection. This research is of great significance for preventing the spread of AIDS among high-risk groups.

　　 The passive immunization method of hepatitis A can provide people with protection for several months before getting an effective vaccine. Previous studies have found that if animals obtain HIV-1 virus antibodies within 1 to 2 days before being exposed to high doses of the virus, they can also show the ability to block viral infections. But the long-term effectiveness of this passive immunotherapy has not been experimentally confirmed. In the new study, Malcolm A. Martin of the National Institute of Allergy and Infectious Diseases and his colleagues hope to solve this problem to confirm whether passive immunotherapy similar to hepatitis A can continue to work against HIV infection. .

　　 Researchers published a paper on the website of "Nature" magazine that they simulated the way humans were infected with HIV on 9 macaques in the control group, and the average time to detect infection was three weeks. Then, they injected a dose of three different antibodies into three groups of six animals each and exposed them to the virus for a week. It was found that the virus infection time of all the antibody groups was delayed. The longest protection period lasted for 23 weeks. The duration of protection was directly related to the antibody strength and half-life. They also discovered that they can extend the half-life of the weakest antibody by introducing mutations in amino acids.

　　 Researchers claim that such antibodies can improve their overall ability to block the spread of drug-resistant HIV-1 virus strains, providing a proof of concept for the prevention and treatment of HIV-1 virus. However, more research is needed to confirm the effectiveness of this therapy in humans and whether it can replace the HIV-1 vaccine.